Trodelvy fails PhIII lung cancer study in blow to Gilead’s ADC expansion plans
Gilead’s antibody-drug conjugate Trodelvy failed to significantly extend survival in a late-stage lung cancer study, the pharma company said Monday morning.
The Phase III EVOKE …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
